Ortiz-Morales, M JoseToledano-Fonseca, MartaMena-Osuna, RafaelCano, M TeresaGomez-España, AuxiliadoraHaba-Rodriguez, Juan R De laRodriguez-Ariza, AntonioAranda, Enrique2023-05-032023-05-032022-06-20Ortiz-Morales MJ, Toledano-Fonseca M, Mena-Osuna R, Cano MT, Gómez-España A, Haba-Rodríguez JR, et al. Basal VEGF-A and ACE Plasma Levels of Metastatic Colorectal Cancer Patients Have Prognostic Value for First-Line Treatment with Chemotherapy Plus Bevacizumab. Cancers (Basel). 2022 Jun 21;14(13):30542072-6694http://hdl.handle.net/10668/20904The identification of factors that respond to anti-angiogenic therapy would represent a significant advance in the therapeutic management of metastatic-colorectal-cancer (mCRC) patients. We previously reported the relevance of VEGF-A and some components of the renin-angiotensin-aldosterone system (RAAS) in the response to anti-angiogenic therapy in cancer patients. Therefore, this prospective study aims to evaluate the prognostic value of basal plasma levels of VEGF-A and angiotensin-converting enzyme (ACE) in 73 mCRC patients who were to receive bevacizumab-based therapies as a first-line treatment. We found that high basal VEGF-A plasma levels were significantly associated with worse overall survival (OS) and progression-free survival (FPS). On the other hand, low ACE levels were significantly associated with poor OS. Importantly, a simple scoring system combining the basal plasma levels of VEGF-A and ACE efficiently stratified mCRC patients, according to OS, into high-risk or low-risk groups, prior to their treatment with bevacizumab. In conclusion, our study supports that VEGF-A and ACE may be potential biomarkers for selecting those mCRC patients who will most benefit from receiving chemotherapy plus bevacizumab treatment in first-line therapy. Additionally, our data reinforce the notion of a close association between the RAAS and the anti-angiogenic response in cancer.enAttribution 4.0 Internationalhttp://creativecommons.org/licenses/by/4.0/VEGF-AAngiotensin-converting enzymeAnti-angiogenic drugBevacizumabBiomarkerColorectal cancerPrognosisBevacizumabVascular endothelial growth factor ARenin-angiotensin systemPrognosisProgression-free survivalColorectal neoplasmsAngiotensinsResearch article35804826open accessAngiotensinasFactor A de crecimiento endotelial vascularNeoplasias colorrectalesPronósticoSistema renina-angiotensinaSupervivencia sin progresión10.3390/cancers14133054PMC9265004https://www.mdpi.com/2072-6694/14/13/3054/pdf?version=1655972800https://www.ncbi.nlm.nih.gov/pmc/articles/PMC9265004/pdf